US › Healthcare

XTL Biopharmaceuticals Ltd ADR (XTLB)

US · Healthcare · Biotechnology

$1.96+2.62%

Last close · 2026-10-16

Latest quarter · ended 2025-03-31

Revenue

$289,000

Net profit

$-255,000

Profit YoY

-152.6%

EPS

$0.00

EPS estimate

$0.00

Net margin

-88.2%

Key statistics

Market cap

$4.9M

Forward P/E

0.0

P/B

1.90

Book value

$0.00

EPS (TTM)

$-0.36

52-week high

$5.96

52-week low

$1.86

50-day MA

$2.48

200-day MA

$2.77

Beta

0.42

Analyst view

with an average price target of $30.00.

Shareholding

Insiders

21.44%

Institutions

0.27%

Largest institutional holders

Fund	Stake
Rhumbline Advisers	0.25%
GAMMA Investing LLC	0.05%
UBS Group AG	0.01%
Morgan Stanley - Brokerage Accounts	0.00%
Noked Israel Ltd	0.00%
Tower Research Capital LLC	0.00%
XTX Topco Ltd	0.00%
SmartHarvest Portfolios, LLC	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for XTL Biopharmaceuticals Ltd ADR — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.